Eisbach Bio
Eisbach Bio is a clinical-stage German biotech that develops first-in-class allosteric small-molecule cancer therapies using its AI-guided ALLOS platform, with lead candidate EIS-12656 (ALC1 inhibitor) in Phase 1/2 trials for HRD cancers at MD Anderson.
- Company typePrivate
- Founded2019
- HeadquartersMunich, Germany
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Eisbach Bio does
Eisbach Bio GmbH is a clinical-stage biotechnology company founded in January 2019 as a spin-off of Ludwig-Maximilians-Universität (LMU) München, headquartered on the Großhadern-Martinsried biotech campus in Planegg near Munich, Germany. The company develops next-generation small-molecule precision oncology drugs through its proprietary ALLOS platform, which conducts wet-lab and computational screens on full-length enzyme complexes in their physiologically activated state. Eisbach trains target-specific large language models on data from these physiological assays to predict novel compounds that can trap molecular targets in their activated state, enabling highly selective allosteric inhibition.
The company's pipeline is centered on synthetic-lethal targeting of cancer-specific vulnerabilities. Its lead candidate, EIS-12656, is a first-in-class, oral, brain-penetrant allosteric inhibitor of the chromatin helicase ALC1 (CHD1L) for homologous recombination deficient (HRD) cancers, currently in a Phase 1/2 MATCH trial (NCT06525298) at MD Anderson Cancer Center with an estimated enrollment of 144 participants. Additional programs include CHD1 (lead optimization, PTEN-deficient tumors), WRN (late preclinical, MSI-high cancers), and EIS-10700, a SARS-CoV-2 helicase inhibitor that completed Phase I in 33 healthy subjects with an excellent safety profile. The company pursues co-development partnerships and grant-funded clinical advancement rather than direct commercialization.
Eisbach generates no commercial revenue and is funded primarily through non-dilutive grants (CPRIT $4.75M, BMBF €8M, StMWi €6.7M) and a $4.5M investment from Cancer Focus Fund LP, anchored to MD Anderson. The firm employs ~15–20 staff and operates across Germany (HQ and discovery) and the United States (clinical operations and trial conduct). Its go-to-market is partnership-driven: licensing, co-development arrangements, or potential acquisition, with future revenue contingent on out-licensing clinical-stage assets rather than direct product sales.
Eisbach Bio firmographics
Firmographics- Name
- Eisbach Bio
- Legal name
- Eisbach Bio GmbH
- Website
- https://eisbach.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Eisbach Bio is a clinical-stage German biotech that develops first-in-class allosteric small-molecule cancer therapies using its AI-guided ALLOS platform, with lead candidate EIS-12656 (ALC1 inhibitor) in Phase 1/2 trials for HRD cancers at MD Anderson.
- Ownership category
- akta.pro rank
Eisbach Bio industry classification
Industry- Product category
- Precision Oncology Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)
- akta.pro secondary industry
- Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Eisbach Bio is headquartered
LocationHeadquarters
- HQ city
- Munich
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Eisbach Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pipeline Development and Licensing: As a clinical-stage biotech, Eisbach Bio does not currently have commercial products. Revenue will come from licensing deals, co-development partnerships, and eventual product commercialization. The company is advancing multiple programs through clinical development.
Go-to-market motion2 records
Distribution channels1 record
Marketing channels3 records
Eisbach Bio product offering
Product offeringCore offering
Eisbach Bio is a clinical-stage biotechnology company developing first-in-class small-molecule cancer medicines that target activated molecular states in chromatin remodeling complexes. Using its proprietary ALLOS platform, which combines AI-guided molecular design with full-length enzyme complex screening, the company engineers allosteric inhibitors for synthetic lethality in cancer, with a lead clinical-stage ALC1 inhibitor (EIS-12656) for HRD cancers. The company also advances preclinical programs targeting CHD1 and WRN helicase, plus a completed Phase I SARS-CoV-2 helicase inhibitor (EIS-10700).
Product overview
Eisbach Bio is a clinical-stage biotechnology company developing next-generation small-molecule cancer therapies through its proprietary ALLOS platform, which leverages AI-guided molecular approaches to target genetically defined cancer vulnerabilities. The company's lead product is EIS-12656, a first-in-class allosteric ALC1 inhibitor currently in Phase 1/2 clinical trials for HRD cancers. The pipeline includes EIS-10700 (completed Phase I as COVID-19 antiviral), CHD1 program in lead optimization for PTEN-deficient tumors, and WRN program in late preclinical development for MSI-high cancers, plus two undisclosed discovery programs in solid tumor oncology.
Differentiator
Problem solved
Functional benefit
Products and services
- EIS-12656 Lead clinical-stage small-molecule allosteric inhibitor of ALC1 (Amplified in Liver Cancer 1), a chromatin remodeling complex member. EIS-12656 is being developed as a synthetic lethality therapy for HRD-deficient cancers, including select breast, ovarian, and other solid tumors with homologous recombination repair deficiencies.
- EIS-10700 Small-molecule inhibitor of SARS-CoV-2 helicase that completed Phase I clinical evaluation. Developed as an antiviral candidate targeting the viral replication machinery.
- CHD1 Program Preclinical oncology drug discovery program targeting CHD1, a chromatin remodeler, applying Eisbach's allosteric drug discovery approach to identify novel small-molecule inhibitors.
- WRN Program Preclinical oncology drug discovery program targeting WRN (Werner syndrome) helicase for MSI-high cancers, leveraging synthetic lethality through allosteric modulation of the chromatin remodeling target.
Quantifiable outcome
- Excellent safety profile demonstrated in Phase I trial: 33 patients received up to 3,000 mg without dose limiting toxicity
- +2 more outcomes
Companies that use Eisbach Bio
Customer profileNamed customers1 record
Segments4 records
Ideal customer profiles1 record
Eisbach Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
Eisbach Bio partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major, core and minor.
- Josep Carreras Leukaemia Research InstitutemajorCoordinator of NUCLEAR Marie Skłodowska Curie Action Doctoral Network. 17 doctoral candidates being trained at interface of metabolism and genome regulation. Eisbach investigating metabolism-chromatin interaction for novel cancer targets.
- The University of Texas MD Anderson Cancer CentercoreStrategic research collaboration to jointly discover and develop precision oncology drugs targeting synthetic lethal engines key to tumor genome evolution. Aligns MD Anderson's Therapeutics Discovery division expertise with Eisbach's discovery platform.
- CTI Clinical Trial & ConsultingmajorSelected as CRO partner providing regulatory and clinical trial management services for the Phase 1/2 MATCH trial of EIS-12656.
- Ludwig-Maximilians-Universität München (LMU)coreEisbach is an LMU spin-off from Großhadern-Martinsried campus. Ongoing collaboration on metabolic regulation of genome function and basic research.
- Core Facility Animal Models (CAM) of LMUmajorCollaboration to test SARS-CoV-2 antivirals. CAM conducts animal studies evaluating drug metabolism and tolerability of Eisbach's inhibitors.
- RocheminorEisbach committed to support C-NATM cluster alongside Roche for at least 3 years developing nucleic acid-based therapeutics.
- C-NATM Cluster PartnersmajorNetwork including leading academic and industrial partners developing innovative therapeutics in nucleic acid chemistry. Led by Prof. Thomas Carell and Prof. Stefan Engelhardt.
- Tubulis GmbHminorPartner in CNATM second funding round, alongside LMU and Coriolis Pharma. Developing therapeutic drugs targeting cancer-driving nucleic acid regulators.
- Coriolis Pharma Research GmbHminorCNATM partner in second funding period, collaborating with Eisbach on intensive R&D activities.
- Precision for HealthminorIndustrial partner in NUCLEAR doctoral network coordinated by Josep Carreras Institute.
- Nusivan GmbHminorClinical trial collaboration in Germany for Phase I study of EIS-10700.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Eisbach Bio competitors and assessment
Company assessmentDirect peers
- Repare Therapeutics: Clinical-stage precision oncology company built around the SNIPRx synthetic-lethality discovery platform, with lead assets targeting DNA-damage-response vulnerabilities analogous to Eisbach's ALC1 program in HRD cancers.
- Tango Therapeutics: Clinical-stage biotech using synthetic-lethality target discovery to develop precision cancer medicines, with programs in HRD and other genetically defined cancers that overlap directly with Eisbach's core oncology thesis.
- Black Diamond Therapeutics: Clinical-stage oncology company developing allosteric, mutation-targeted small molecules against cancer drivers, sharing Eisbach's emphasis on allosteric mechanism and genetically defined patient populations.
- Vivace Therapeutics: Clinical-stage oncology company focused on allosteric small-molecule inhibitors of cancer targets, making it a direct methodological peer to Eisbach's allosteric ALC1 strategy.
- Foghorn Therapeutics: Clinical-stage biotech developing medicines against chromatin biology targets, directly comparable to Eisbach's ALC1 and CHD1 programs in chromatin remodeling.
- Accent Therapeutics: Clinical-stage precision oncology company targeting RNA-modifying and chromatin regulators, sharing Eisbach's strategy of drugging genetically defined cancer dependencies with allosteric or targeted small molecules.
- Relay Therapeutics: Clinical-stage precision oncology company integrating computation and structural biology to design targeted therapies, comparable to Eisbach in its AI/structural-biology-driven approach to genetically defined cancers.
Emerging players
- Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning, comparable to Eisbach in its thesis that AI-guided platforms can accelerate first-in-class small-molecule discovery.
- Exscientia: AI-native precision medicine company using its platform to design small-molecule drugs, overlapping with Eisbach's positioning of ALLOS as an AI-guided discovery engine for precision oncology.
Broad incumbents
- Schrödinger: Established computational chemistry and molecular simulation company with a therapeutics pipeline and platform tools for structure-based drug design, relevant to Eisbach's computational screening and structure-guided allosteric design work.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eisbach Bio social profiles
Digital presenceEisbach Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eisbach Bio leadership team
Management profileNumber of profiles
Profiles2 records
Eisbach Bio funding detail
Funding detailFunding overview
Funding rounds3 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eisbach Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eisbach Bio
What does Eisbach Bio do?
Eisbach Bio is a clinical-stage biotechnology company developing first-in-class small-molecule cancer medicines that target activated molecular states in chromatin remodeling complexes. Using its proprietary ALLOS platform, which combines AI-guided molecular design with full-length enzyme complex screening, the company engineers allosteric inhibitors for synthetic lethality in cancer, with a lead clinical-stage ALC1 inhibitor (EIS-12656) for HRD cancers. The company also advances preclinical programs targeting CHD1 and WRN helicase, plus a completed Phase I SARS-CoV-2 helicase inhibitor (EIS-10700).
Is Eisbach Bio a public or private company?
Eisbach Bio is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eisbach Bio founded?
Eisbach Bio was founded in 2019. It employs 11 to 50 people.
Where is Eisbach Bio based?
Eisbach Bio is headquartered in Munich, Germany, in the Europe region.
How does Eisbach Bio make money?
One revenue line is on record: pipeline Development and Licensing.
Who are Eisbach Bio's main competitors?
Direct peers on record are Repare Therapeutics, Tango Therapeutics, Black Diamond Therapeutics, Vivace Therapeutics, Foghorn Therapeutics, Accent Therapeutics and Relay Therapeutics. Emerging players are Recursion Pharmaceuticals and Exscientia. Schrödinger is listed as a broad incumbent.
Does Eisbach Bio have an API?
No public API is recorded for Eisbach Bio.
What industry is Eisbach Bio in?
Eisbach Bio's product category is Precision Oncology Therapeutics. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 8731.